Amprenavir
DefinitionThis section has been translated automatically.
Virustatic. Inhibitor of HIV protease.
IndicationThis section has been translated automatically.
Antiretroviral combination therapy for the treatment of HIV-1 infection in protease inhibitor pretreated patients > 4 years.
Notice!
Consideration of the viral resistance pattern and pretreatment of the patient especially with other protease inhibitors!Pregnancy/nursing periodThis section has been translated automatically.
Contraindicated (insufficient data, substance is placental) in pregnancy. For treatment during lactation: weaning.
Dosage and method of useThis section has been translated automatically.
- Total: Adults and children > 4 years 3 times/day 17 mg (1,1 ml)/kg bw p.o. in combination with other antiretroviral drugs, maximum daily dose: 2800 mg.
- adult and adolescent > 12 J. (patient > 50 kg bw): 2 times/day 1200 mg p.o. in combination with other antiretroviral drugs. In combination with ritonavir (2 times/day 100 mg p.o.): dose reduction to 600 mg p.o. 2 times/day. Maximum daily dose: 2400 mg. For patients with moderate or severe liver dysfunction: dose reduction to 450 mg twice daily or 300 mg twice daily. Children 4-12 years of age, patients < 50 kg bw: 20 mg/kg bw, maximum daily dose: 2400 mg.
Undesirable effectsThis section has been translated automatically.
Gastrointestinal symptoms (10-30% of patients) such as nausea, vomiting, diarrhea, cutaneous NW (10-20% of patients) such as erythema, erythema exudativum multiforme, headache (about 10% of patients), fatigue.
ContraindicationThis section has been translated automatically.
Patient with severe liver and kidney dysfunction (e.g. WHO group III-IV), children < 4 years. Comedication with rifampicin or CYP3A4 substrates such as terfenadine, St. John's wort, cisapride, pimozide, antidepressants (e.g. diazepam, midazolam, flurazepam), ergotamine derivatives, astemizole, etc.
PreparationsThis section has been translated automatically.
Agenerase
LiteratureThis section has been translated automatically.
- Eron JJ JR (2002) HIV-1 protease inhibitors. Clin Infect Dis 30: 160-170